

C3 Glomerulopathy: From Early Recognition to Individualized Targeted Therapy

Reference List

Ahmad SB, Bomback AS. C3 glomerulopathy: Pathogenesis and treatment. *Adv Chronic Kidney Dis*. 2020;27(2):104–110. doi:10.1053/j.ackd.2019.12.003

American Kidney Fund. Me + C3G Anne's Story [video]. YouTube. Published March 5, 2024. Accessed August 17, 2026. <https://www.youtube.com/watch?v=3feNqm7Y3Cg>

Apellis Pharmaceuticals, Inc. An open-label nonrandomized, multicenter extension study to evaluate the long-term safety and efficacy of pegcetacoplan in participants with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis (VALE). Updated April 2, 2026. Accessed August 15, 2026. <https://clinicaltrials.gov/study/NCT05809531>

Bomback AS. Anti-complement therapy for glomerular diseases. *Adv Chronic Kidney Dis*. 2014;21(2):152–158. doi:10.1053/j.ackd.2013.12.001

Bomback AS, Santoriello D, Avasare RS, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. *Kidney Int*. 2018;93(4):977–985. doi:10.1016/j.kint.2017.10.022

Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, et al. Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease. *Clin J Am Soc Nephrol*. 2020;15(9):1287–1298. doi:10.2215/cjn.15241219

Caravaca-Fontán F, Fakhouri F, Licht C, et al. Delphi consensus on surrogate end points in C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis. *Kidney Int Rep*. 2025;11(2):103671. doi:10.1016/j.ekir.2025.10.028

Empaveli. Prescribing Information. Apellis Pharmaceuticals; 2025. Accessed August 17, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215014s011lbl.pdf -

Fabhalta. Prescribing Information. Novartis Pharmaceuticals Corporation; 2025. Accessed August 17, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218276s007lbl.pdf -

Fakhouri F, Bomback AS, Ariceta G, et al. Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN. *N Engl J Med*. 2025;393(22):2210–2220. doi:10.1056/NEJMoa2501510

Kavanagh D, Bomback AS, Vivarelli M, et al. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. *Lancet*. 2025;406(10512):1587–1598. doi:10.1016/s0140-6736(25)01148-1

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021;100(4S):S1–S276. doi:10.1016/j.kint.2021.05.021

Le Quintrec M, Lapeyraque AL, Lionet A, et al. Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. *Am J Kidney Dis*. 2018;72(1):84–92. doi:10.1053/j.ajkd.2017.11.019

C3 Glomerulopathy: From Early Recognition to Individualized Targeted Therapy

Mashayekhi M, Zuckerman JE, Barratt J, et al. C3 glomerulopathy diagnosis, current treatments, and emerging therapies. *Kidney Med.* 2026;8(3):101258. doi:10.1016/j.xkme.2026.101258

Novartis Pharmaceuticals. Long-term efficacy, safety, and tolerability of iptacopan in C3G or IC-MPGN. Updated August 7, 2026. Accessed August 15, 2026. <https://clinicaltrials.gov/study/NCT03955445>

Overwijk RH, Kolbinger FR, Eijgelsheim M, et al. A decade of C3 glomerulopathy-a nationwide cohort study. *Kidney Int Rep.* 2025;11(2):103681. doi:10.1016/j.ekir.2025.11.007

Servais A, Frémeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. *J Med Genet.* 2007;44(3):193–199. doi:10.1136/jmg.2006.045328

Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy — understanding a rare complement-driven renal disease. *Nat Rev Nephrol.* 2019;15(3):129–143. doi:10.1038/s41581-018-0107-2